IGC Pharma Begins Patient Enrollment for Phase 2 Alzheimer’s Agitation Trial at Neurostudies IGC Pharma has commenced patient enrollment at Neurostudies, Inc. in Port Charlotte, Florida, for its Phase 2 clinical trial investigating IGC-AD1 as a potential treatment for agitation…
A Journey from Curiosity About Life on Earth to Transformative Therapies at Novartis When I was young, my fascination with science began with the natural world and animals. A BBC Nature presenter and biologist, David Attenborough, was a significant idol…
A biopharmaceutical company specializing in genetic diseases and cancers has unveiled plans to present a series of findings at the 2024 International Symposium on Amyloidosis (ISA) in Rochester, Minnesota, from May 26 to May 30, 2024. BridgeBio Pharma will showcase…
Monkeypox, a viral disease, continues its global impact. Today, the World Health Organization (WHO) unveiled a new strategic framework aimed at guiding efforts to prevent and manage monkeypox outbreaks. The framework targets the elimination of human-to-human transmission and the reduction…
In the latest release of the World Health Statistics by the World Health Organization (WHO), the impact of the COVID-19 pandemic on global life expectancy and healthy life expectancy at birth (HALE) is starkly evident. The pandemic has reversed the…
Eisai has announced its participation in the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), held both virtually and in-person in Chicago, Illinois from May 31 to June 4. They are presenting research from their oncology portfolio and…
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) have announced the publication of groundbreaking findings in Nature Communications, revealing the results from a comprehensive phase 1/2/3a/3b study investigating the safety, immune response, and effectiveness of ARCT-154, a pioneering self-amplifying (sa-mRNA)…
Bristol Myers Squibb (NYSE: BMY) has unveiled the Live Your PosSCZible campaign, a nationwide initiative developed in collaboration with the schizophrenia community. The campaign aims to amplify firsthand experiences and equip patients and caregivers with educational tools, community connections, and…
Bristol Myers Squibb (NYSE: BMY) has unveiled the Live Your PosSCZible campaign, a nationwide initiative in collaboration with the schizophrenia community. The campaign aims to amplify personal experiences, offering educational resources, community connections, and peer support to empower patients and…
Eli Lilly’s Mirikizumab Shows Promise in Phase 3 Study for Crohn’s Disease In Eli Lilly and Company’s pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn’s disease, regardless of previous biologic failure, showed significant and meaningful improvements…
Guardant Health, Inc. (Nasdaq: GH), a prominent player in precision oncology, disclosed today that its Compensation Committee, on April 22, 2024, sanctioned the allocation of restricted stock units (“RSUs”) corresponding to 215,601 shares of its common stock for 94 newly…
MAIA Biotechnology, Inc. (NYSE American: MAIA), a pioneering company focused on developing immunotherapies targeting telomeres for cancer treatment, has confirmed its participation in the prestigious BIO International Convention scheduled from June 3 to June 6, 2024, in San Diego, California.…